Dosing & Uses
Dosage Forms & Strengths
tablet
- 5mg
- 7.5mg
- 10mg
capsule, extended-release
- 15mg
- 30mg
Muscle Spasm
Immediate-release tablet
- 5 mg PO q8hr; may increase dose to 7.5-10 mg PO q8hr PRN
Extended-release capsule
- 15 mg PO qDay; some patients may require up to 30 mg PO qDay
Dosing Modifications
Hepatic impairment
- Immediate-release tablet: 5 mg/day PO initially; titrate slowly and consider less frequent dosing
- Extended-release capsule: Not recommended in mild-to-severe hepatic impairment
Renal Impairment
- Not studied
Dosage Forms & Strengths
tablet
- 5mg
- 7.5mg
- 10mg
Muscle Spasm
Immediate-release tablet
- <15 years: Safety and efficacy not established
- >15 years: 5 mg PO q8hr; may increase dose to 7.5-10 mg PO q8hr PRN
Extended-release capsule
- <18 years: Safety and efficacy not established
- >18 years: 15 mg PO qDay; some patients may require up to 30 mg PO qDay
Muscle Spasm
Immediate-release tablet: 5 mg/day PO initially; titrate slowly upward and consider less frequent dosing
Extended-release capsule not recommended in elderly, because of increased plasma levels (40%) and prolonged half-life (56%) compared with young adults
Interactions
Interaction Checker
No Results

Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor

Adverse Effects
>10%
Drowsiness (up to 39% immediate-release; 100% extended-release)
Dry mouth (21-32%)
Dizziness (3-11%)
1-10%
Pharyngitis (1-3%)
Headache (1-5%)
Fatigue (6%)
Palpitations (6%)
Bad taste in mouth (1-6%)
Indigestion (4%)
Blurred vision (3%)
Constipation (1-3%)
Asthenia (1-3%)
Confusion (1-3%)
Nausea (1-3%)
Nervousness (1-3%)
<1%
Arrhythmia
Hypotension
Palpitation
Syncope
Tachycardia
Vasodilation
Cardiac dysrhythmia (rare)
Cholestasis (rare)
Hepatitis
Jaundice
Anaphylaxis (rare)
Immune hypersensitivity reaction
Postmarketing Reports
Serotonin syndrome
Hypertension
Stroke
Heart block
Myocardial infarction
Warnings
Contraindications
Hypersensitivity to drug or formulation components
Hyperthyroidism
During the acute recovery phase of myocardial infarction and in patients with arrhythmia, heart block or conduction disturbances, or congestive heart failure
Concomitant use or within 14 days of discontinuing MAO inhibitors
Hyperpyretic crisis seizures and deaths have occurred in patients receiving cyclobenzaprine (or structurally similar tricyclic antidepressants) concomitantly with MAO inhibitors
Cautions
Use only for short periods (2-3 wk)
Use caution in urinary retention, narrow-angle glaucoma or IOP, or concomitant use of other anticholinergic drugs
May cause drowsiness/dizziness; do not ingest alcohol or other CNS depressants; may impair ability to operate heavy machinery
May take with food to avoid stomach upset
Serotonin syndrome reported when coadministered with other drugs that increase serotonin (eg, SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors [see also Contraindications])
Not effective for treatment of spasticity associated with cerebral/spinal cord disease or for pediatric cerebral palsy
Elderly patients may be more prone to adverse effects and require dose/frequency reduction
Use immediate release with caution in hepatic impairment; extended-release form not recommended with hepatic impairment
Pregnancy & Lactation
Pregnancy
Available data from case reports with use in pregnancy have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes
Animal data
- In rats, decreased pup body weight and survival was noted at cyclobenzaprine doses ≥10 mg/kg/day (approximately ≥3 times maximum recommended human dose (MRHD) of 30 mg/day), when administered orally during pregnancy and lactation
Lactation
There are no data on presence of drug in either human or animal milk, the effects on a breastfed infant, or effects on milk production; developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed child from therapy or from underlying maternal condition.
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Relieves local skeletal muscle spasm; clinical response similar to diazepam
Structurally related to cyclic antidepressants, and pharmacologic effects are similar, including reserpine antagonism, norepinephrine potentiation, potent peripheral and central anticholinergic effects, and sedation; reduces tonic somatic motor activity influencing alpha and gamma motor neurons
Absorption
Onset: 1 hr
Duration: 12-24 hr
Bioavailability: 33-55%
Peak plasma time: 7-8 hr
Peak plasma concentration: 15-25 ng/mL
Distribution
Protein bound: 93%
Metabolism
Hepatic via CYP3A4, 1A2, and 2D6; may undergo enterohepatic recirculation
Elimination
Half-life: 8-37 hours (immediate release); 32-33 hr (extended release)
Excretion: Urine, feces
Images
Patient Handout
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.